Vectorite Biomedical Inc (4170) Fair Value & Analysis
Healthcare · TW · Market cap 571M TWD (≈ $18.1M) · ISIN TW0004170006
What is Vectorite Biomedical Inc really worth?
A solid business, trading 67% below our fair value of 36.78 TWD.
As of Sep 6, 2026, the fair value of Vectorite Biomedical Inc is 36.78 TWD per share against a price of 12.30 TWD, so the fair value sits 199% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Sep 6, 2026
From 10 valuation models · updated today
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case (27.58 TWD). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (27.58 TWD to 57.95 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 6, 2026.
How to read this chart
60‑month range 11.30 TWD – 23.80 TWD · fair‑value band 27.58 TWD – 57.95 TWD · the 12.30 TWD price screens below the 36.78 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 6, 2026.
Analysis
Vectorite Biomedical Inc (4170) currently trades at 12.30 TWD, while our model-based Fair Value estimate is 36.78 TWD, implying the stock looks roughly 66.6% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 44.57 TWD per share, and 8 of the 10 models we run sit above the 12.30 TWD price. Bear case: the Asset-Based group reads lowest at 7.42 TWD, and 2 of the 10 models stay below the price. Evidence for this calculation is low.
Trailing-twelve-month revenue stands at 61.4M TWD. Revenue declined 19.0% year over year. It earns a return on equity of 22.0%. The balance sheet holds a net cash position of 30.6M TWD. Fundamentals as of Sep 6, 2026
Our scenario range runs from 27.58 TWD (bear case) to 57.95 TWD (bull case); at 12.30 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at 199%, 4170 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 1.49 TWD per share, which is 4.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 10 models by family
Widest divergence: Growth Earnings (44.57 TWD) versus Asset-Based (7.42 TWD). Highest evidence: Owner Earnings (72).
Notify me when 4170 reaches fair value
Put 4170 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc.
Full company description
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vectorite Biomedical Inc reported revenue of 61.4M TWD in FY2025 versus 28.8M TWD in FY2021, a compound +20.9%/yr. Reported net income was 96.2M TWD in FY2025, compounding +84.2%/yr from FY2021.
Watch 4170: get an alert when its fair value changes →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Vectorite Biomedical Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vectorite Biomedical Inc (4170) overvalued or undervalued?
What is the fair value of 4170?
What is the quality score of 4170?
What is the price target for Vectorite Biomedical Inc (4170)?
What is the Vectorite Biomedical Inc stock forecast for 2026?
What is the revenue of Vectorite Biomedical Inc (4170)?
What is the net profit margin of 4170?
Watch Vectorite Biomedical Inc in the live analysis
One click puts Vectorite Biomedical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.